Chemistry:Indantadol
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C11H14N2O |
| Molar mass | 190.246 g·mol−1 |
| 3D model (JSmol) | |
| |
Indantadol (CHF-3381, V-3381) is a drug which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi.[1][2][3][4][5][6][7][8] It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor,[5][6][9] and as a low affinity, non-competitive NMDA receptor antagonist.[1][2][10] A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in phase IIb clinical trials.[7][8][11][12]
See also
References
- ↑ 1.0 1.1 "Preclinical evaluation of CHF3381 as a novel antiepileptic agent". Neuropharmacology 40 (7): 866–78. June 2001. doi:10.1016/S0028-3908(01)00026-0. PMID 11378157.
- ↑ 2.0 2.1 "Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms". Pharmacology Biochemistry and Behavior 70 (1): 157–66. September 2001. doi:10.1016/S0091-3057(01)00591-3. PMID 11566153.
- ↑ "Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist". NeuroReport 13 (16): 2071–4. November 2002. doi:10.1097/00001756-200211150-00016. PMID 12438928.
- ↑ "Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain". The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804–14. August 2003. doi:10.1124/jpet.103.050039. PMID 12750440.
- ↑ 5.0 5.1 "CHF 3381". Drugs in R&D 5 (1): 28–30. 2004. doi:10.2165/00126839-200405010-00005. PMID 14725488.
- ↑ 6.0 6.1 "Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain". IDrugs: The Investigational Drugs Journal 10 (9): 636–44. September 2007. PMID 17786847.
- ↑ 7.0 7.1 "IN-STEP Phase IIb study results". http://www.vernalis.com/media-centre/latest-releases/567-in-step-phase-iib-study-results-.
- ↑ 8.0 8.1 "Vernalis initiates Pilot Study of V3381 in patients with chronic cough". http://www.vernalis.com/media-centre/latest-releases/2009-releases/389.
- ↑ "CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model". The Journal of Pain 7 (8): 565–74. August 2006. doi:10.1016/j.jpain.2006.02.004. PMID 16885013.
- ↑ "Mechanisms of action of CHF3381 in the forebrain". British Journal of Pharmacology 139 (7): 1333–41. August 2003. doi:10.1038/sj.bjp.0705381. PMID 12890713.
- ↑ "V3381CC". http://www.vernalis.com/component/content/article/387.
- ↑ "Vernalis completes recruitment in V3381 Phase II IN-STEP study for neuropathic pain". http://www.vernalis.com/media-centre/latest-releases/2009-releases/391.
 |  |
